Brief: Arrivent Announces First Patient Dosed In Global Pivotal Phase 3 Alpacca Trial Evaluating Firmonertinib For First-Line Treatment Of EGFR PACC Mutant Non-Small Cell Lung Cancer
22/12/2025 13:20
Dec 22 (Reuters) - Arrivent Biopharma Inc AVBP.O: ARRIVENT ANNOUNCES FIRST PATIENT DOSED IN GLOBAL PIVOTAL PHASE 3 ALPACCA TRIAL EVALUATING FIRMONERTINIB FOR FIRST-LINE TREATMENT OF EGFR PACC MUTANT NON-SMALL CELL LUNG CANCER Source text: ID:nGNXJ44p Further company coverage: AVBP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ArriVent BioPharma
See all newsBrief: Arrivent Announces First Patient Dosed With Novel Tetravalent Muc16/Napi2b Dual Target Adc, Arr-002
US RESEARCH ROUNDUP-Allstate, Caribou Biosciences, Zscaler
U.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
ArriVent falls after lung cancer drug misses late-stage trial goal